TipRanks
aTyr Pharma (DE:471A)
FRANKFURT:471A
Germany Market
471A
aTyr Pharma
RESEARCH TOOLSreports

aTyr Pharma (471A) Stock Forecast & Price Target

14 Followers
See the Price Targets and Ratings of:

471A Analyst Ratings

Hold
5Ratings
Hold
1 Buy
4 Hold
0 Sell
Based on 5 analysts giving stock ratings to
aTyr
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

471A Stock 12 Month Forecast

Average Price Target

€2.63
▲(674.63% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is €2.63 with a high forecast of €6.15 and a low forecast of €0.88. The average price target represents a 674.63% change from the last price of €0.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.14537497,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.63373213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.87791071,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.358,0.80318269,1.24836538,1.6935480699999998,2.13873076,2.5839134500000003,3.02909614,3.47427883,3.91946152,4.36464421,4.8098269,5.255009589999999,5.70019228,{"y":6.14537497,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.358,0.5330563176923077,0.7081126353846153,0.883168953076923,1.0582252707692308,1.2332815884615385,1.4083379061538461,1.5833942238461538,1.7584505415384615,1.9335068592307691,2.108563176923077,2.2836194946153845,2.458675812307692,{"y":2.63373213,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.358,0.3979931315384615,0.43798626307692307,0.47797939461538463,0.5179725261538461,0.5579656576923077,0.5979587892307692,0.6379519207692308,0.6779450523076923,0.7179381838461538,0.7579313153846154,0.797924446923077,0.8379175784615385,{"y":0.87791071,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.755,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.615,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.552,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.356,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.419,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.358,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€6.15Average Price Target€2.63Lowest Price Target€0.88
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:471A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (NASDAQ: AYTU), Surrozen (NASDAQ: SRZN) and aTyr Pharma (NASDAQ: ATYR)
JonesTrading Analyst forecast on DE:471A
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (NASDAQ: EMBC) and aTyr Pharma (NASDAQ: ATYR)
Wells Fargo Analyst forecast on DE:471A
Derek Archila
Wells Fargo
Wells Fargo
€0.88
Hold
158.21%
Upside
Assigned
08/10/26
aTyr Pharma (ATYR) Receives a Hold from Wells Fargo
RBC Capital Analyst forecast on DE:471A
Brian Abrahams
RBC Capital
RBC Capital
€0.88
Hold
158.21%
Upside
Reiterated
08/09/26
RBC Capital Sticks to Their Hold Rating for aTyr Pharma (ATYR)
Piper Sandler Analyst forecast on DE:471A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€6.15
Buy
1707.46%
Upside
Reiterated
07/16/26
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
Freedom Capital Markets Analyst forecast on DE:471A
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€0.88→€3.07
Buy
803.73%
Upside
Upgraded
05/20/26
aTyr Pharma upgraded to Buy from Hold at Freedom BrokeraTyr Pharma upgraded to Buy from Hold at Freedom Broker
Jefferies Analyst forecast on DE:471A
Faisal Khurshid
Jefferies
Jefferies
―
Hold
―
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:471A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
09/24/26
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (NASDAQ: AYTU), Surrozen (NASDAQ: SRZN) and aTyr Pharma (NASDAQ: ATYR)
JonesTrading Analyst forecast on DE:471A
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
08/10/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (NASDAQ: EMBC) and aTyr Pharma (NASDAQ: ATYR)
Wells Fargo Analyst forecast on DE:471A
Derek Archila
Wells Fargo
Wells Fargo
€0.88
Hold
158.21%
Upside
Assigned
08/10/26
aTyr Pharma (ATYR) Receives a Hold from Wells Fargo
RBC Capital Analyst forecast on DE:471A
Brian Abrahams
RBC Capital
RBC Capital
€0.88
Hold
158.21%
Upside
Reiterated
08/09/26
RBC Capital Sticks to Their Hold Rating for aTyr Pharma (ATYR)
Piper Sandler Analyst forecast on DE:471A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€6.15
Buy
1707.46%
Upside
Reiterated
07/16/26
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
Freedom Capital Markets Analyst forecast on DE:471A
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€0.88→€3.07
Buy
803.73%
Upside
Upgraded
05/20/26
aTyr Pharma upgraded to Buy from Hold at Freedom BrokeraTyr Pharma upgraded to Buy from Hold at Freedom Broker
Jefferies Analyst forecast on DE:471A
Faisal Khurshid
Jefferies
Jefferies
―
Hold
―
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
WSTWest Pharmaceutical Services
OMCLOmnicell
ACHVAchieve Life Sciences
LFMDLifeMD
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering aTyr Pharma

3 Months
Yasmeen RahimiPiper Sandler
Success Rate
8/13 ratings generated profit
62%
Average Return
+8.56%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +8.56% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
3/13 ratings generated profit
23%
Average Return
-19.65%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -19.65% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
0/13 ratings generated profit
0%
Average Return
-65.34%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -65.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

471A Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
3
2
4
2
2
Buy
0
0
0
0
0
Hold
9
7
9
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
9
13
10
10
In the current month, 471A has received 2 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 471A average Analyst price target in the past 3 months is 2.63.
Each month's total comprises the sum of three months' worth of ratings.

471A Financial Forecast

471A Earnings Forecast

Next quarter’s earnings estimate for 471A is -€0.09 with a range of -€0.11 to -€0.07. The previous quarter’s EPS was -€0.10. 471A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.
Next quarter’s earnings estimate for 471A is -€0.09 with a range of -€0.11 to -€0.07. The previous quarter’s EPS was -€0.10. 471A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.

471A Sales Forecast

Next quarter’s sales forecast for 471A is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 471A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.
Next quarter’s sales forecast for 471A is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 471A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.

471A Stock Forecast FAQ

What is DE:471A’s average 12-month price target, according to analysts?
Based on analyst ratings, aTyr Pharma’s 12-month average price target is 2.63.
    What is DE:471A’s upside potential, based on the analysts’ average price target?
    aTyr Pharma has 674.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is aTyr Pharma a Buy, Sell or Hold?
          aTyr Pharma has a consensus rating of Hold, which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
            What is aTyr Pharma’s share price target?
            The average share price target for aTyr Pharma is 2.63. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €6.15 ,and the lowest forecast is €0.88. The average share price target represents 674.63% Increase from the current price of €0.34.
              What do analysts say about aTyr Pharma?
              aTyr Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of aTyr Pharma?
                To buy shares of DE:471A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.